To increase the effectiveness of cancer therapy, combination therapies including immunotherapy and AST have recently been used, and a clinical trial in this field showed that administration of DC-vaccine (Provenge) before AST led to an increase of effective cytokines such as IFN-γ along with tumor-specific T cells in men with hormone-sensitive patients biochemically recurrent prostate cancer PC (115). The gene discussed is IFNG; the disease is neoplasm.